Innovent and Roche Partner to Advance Novel DLL3-Targeted ADC, IBI3009

Innovent Biologics, a top-tier biopharmaceutical firm focused on creating, producing, and marketing high-quality drugs for oncology, cardiovascular and metabolic diseases, autoimmune disorders, ophthalmology, and various other serious illnesses, has announced a partnership and exclusive licensing agreement with Roche to enhance the progression of IBI3009, a new DLL3-targeted antibody drug conjugate (ADC) candidate.

IBI3009 has received IND approvals in Australia, China, and the United States, and the first patient in the Phase 1 clinical trial was dosed in December 2024. This partnership seeks to deliver groundbreaking treatment choices to individuals suffering from advanced small cell lung cancer.

According to the agreement, Innovent has provided Roche with exclusive worldwide rights to develop, produce, and market IBI3009. The two parties will collaboratively concentrate on the initial development of this ADC candidate, after which Roche will assume complete development. Innovent will obtain an initial payment of US$80 million and can earn up to US$1 billion in development and commercial milestone payments, as well as tiered royalties based on net sales.

Created using Innovent's unique and innovative topoisomerase 1 inhibitor (TOPO1i) platform, IBI3009 ranks among the top and potentially best-in-class DLL3-targeting ADCs. IBI3009 has demonstrated promising anti-tumor effects in various tumor-bearing mouse models, especially in chemotherapy-resistant tumor types, and has exhibited a positive safety profile.